Scotland receives superb value from the latest medicines and vaccines thanks to robust measures which ensure NHS Scotland uses treatments that are both cost and clinically effective.
The UK has robust measures in place to ensure that medicines and vaccines are both clinically and cost effective before they can be used in the NHS.
The ABPI has produced this sourcebook to support pharmaceutical companies in working successfully and collaboratively with patients and patient organisations.
Illness never sleeps. It grows, mutates and causes pain and suffering. Disease never takes a break, so neither do we. Because people fighting disease deserve the best chance to live.
Medicines and vaccines are some of the most important ways we have to fight disease on a global scale and keep people fit and healthy.
28 January 2020
In a week that has seen a Global Talent visa launched, the ABPI has welcomed the Government’s ambition to build a future immigration system which supports the UK’s thriving life sciences sector.
22 January 2020
The DHSC has announced a consultation into the Statutory Scheme. This looks at amending the payment percentages in the Branded Health Service Medicines (Costs) Regulations 2018.
21 January 2020
NHS Scotland will receive £70 million from a scheme which helps keep medicines costs under control, according to new data released by ABPI Scotland in the first session of the Scottish Parliament’s Health and Sport Committee Inquiry into medicines.
14 January 2020
Novartis has announced a collaboration with NHS England, the National Institute for Health Research and Oxford University.
06 January 2020
Recommendations have been published in the British Journal of Cancer on how best to conduct Complex Innovative Design (CID) trials. Dr Ali Hansford, Head of Regulatory Strategy Policy, looks into these recommendations in more detail.
15 November 2019
The ABPI's President Haseeb Ahmad has written a comment piece on the launch of our 2020 Manifesto for Medicine.